Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.58 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | DHODH | Q02127 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | IKBKB | O14920 | 2/20 | 0.49 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13388756 | 0.86 | SCN3A (0.64) | SCN3ASCN9ALMNADHODHJAK2 | |
| SCHEMBL14828738 | 0.85 | SCN3A (0.59) | SCN3ASCN9AHSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL12489110 | 0.85 | SCN3A (0.59) | SCN3ASCN9AHSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL12489758 | 0.84 | SCN3A (0.57) | SCN3ASCN9ADHODHJAK2PDGFRB | |
| SCHEMBL10222766 | 0.81 | ALDH1A1 (0.58) | SCN3ASCN9AHSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL1752153 | 0.81 | SCN3A (0.59) | SCN3ASCN9AHPGDSMN1; SMN2MEN1 | |
| SCHEMBL17676966 | 0.81 | SCN3A (0.59) | SCN3ASCN9AHPGDSMN1; SMN2MEN1 | |
| SCHEMBL17676961 | 0.81 | SCN3A (0.59) | SCN3ASCN9AHPGDSMN1; SMN2MEN1 | |
| SCHEMBL10223615 | 0.79 | SCN3A (0.50) | SCN3ASCN9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL7692273 | 0.79 | SCN3A (0.56) | SCN3ASCN9AHSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-8362020-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362020-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | SCN3A 4081/4885SCN9A 3921/4885HSD17B10 2037/4885 |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | SCN3A 4081/4885SCN9A 3921/4885HSD17B10 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.